- Research article
- Open Access
Significant pain variability in persons with, or at high risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of cohort data
BMC Musculoskeletal Disorders volume 18, Article number: 80 (2017)
While knee osteoarthritis (OA) is characterised as a slowly progressive disease, acute flares, episodes of severe pain, and substantial fluctuations in pain intensity appear to be part of the natural history for some patients. We sought to estimate what proportion of symptomatic community-dwelling adults might be affected, and to identify patient and problem characteristics associated with higher risk of such variability in pain.
We analysed data collected at baseline, 18, 36, 54, and 72 month follow-up of a prospective cohort of symptomatic adults aged over 50 years with current/recent knee pain. At each time point we estimated the proportion of participants reporting 'significant pain variability' (defined as worst pain intensity in the past 6 months ≥5/10 and ≥2 points higher than average pain intensity during the same 6-month period). The associations between significant pain variability and demographic, socioeconomic, lifestyle, clinical, radiographic, and healthcare utilisation factors measured at baseline were estimated by adjusted odds ratios and 95% confidence intervals (aOR; 95%CI) from multivariable discrete-time survival analysis.
Seven hundred and nineteen participants were included in the final analysis. At each time point, 23–32% of participants were classed as reporting significant pain variability. Associated factors included: younger age (aOR (per year): 0.96; 95% CI 0.94, 0.97), higher BMI (per kg/m2:1.03; 1.01, 1.06), higher WOMAC Pain score (per unit: 1.06; 1.03, 1.10), longer time since onset (e.g. 1–5 years vs < 1 year: 1.79; 1.16, 2.75) and morning stiffness (≤30 min vs none: 1.43; 1.10, 1.85). The models accounting for multiple periods of significant symptom variability found similar associations.
Our findings are consistent with studies showing that, for some patients OA symptoms are significantly variable over time. Future prospective studies on the nature and frequency of flare ups are needed to help determine triggers and their underlying pathophysiology in order to suggest new avenues for effective episode management of OA to complement long-term behaviour change.
Longitudinal studies of knee osteoarthritis (OA) with repeated measurements over 5-6 years have suggested that symptoms typically follow relatively stable long-term trajectories [1–5]. However, these can mask considerable within-person variability [6–8]. Of particular interest are acute flares and episodes of uncharacteristically severe pain that have been suggested to occur in both the early and advanced stages of OA and which are associated with distress and loss of function, particularly when unpredictable .
Flare design trials, in which usual medication is withdrawn with the intention of inducing an acute increase in pain within a specified time period are well established. For example, a recent systematic review identified 33 definite or possible flare design trials evaluating non-steroidal anti-inflammatory drugs (NSAID) . The ‘natural occurrence’ of such flares has received less attention although there is a growing body of observational research on these phenomena under a variety of labels (“flares”, “acute events”, “episodes”, “exacerbations”). These include studies that have attempted to define an osteoarthritis flare [11, 12], to understand the role of inflammation in these acute events [13, 14], to identify triggers  and to describe their impact on productivity .
Despite this growing body of research there is an outstanding gap of epidemiological evidence on how common these flare ups may be and the type of patients that are experiencing them. The largest quantitative study by Marty et al.  produced a scoring tool to determine those experiencing potential knee OA flare ups but this has not yet been widely adopted clinically or in research. Factors that have been critically important in defining flare ups in other diseases may be important in osteoarthritis. These include worsening of symptoms beyond normal day-to-day variation requiring additional medication [17–19], that is progressive  and is clinically significant . Looking at significant symptom variability in osteoarthritis is a starting point.
The aim of our study was to generate a preliminary initial estimate of the frequency of significant symptom variability in a primary care population and assess if there were any risk factors associated with them.
This was a secondary analysis of prospective observational cohort data from a sample of community-dwelling symptomatic adults – the Clinical Assessment Study of the Knee (CAS(K)).
Participants were recruited from a two-stage cross-sectional postal survey of all adults ages ≥50 years registered with three general practices in North Staffordshire (irrespective of actual consulting patterns). Respondents reporting pain of any duration in or around the knee within the previous 12 months were invited to attend a research clinic at a local National Health Service Hospital Trust. The study protocol was approved by North Staffordshire Local Research Ethics Committee (project number 1430) and details have been published elsewhere [22, 23]. All participants provided written informed consent to undergo clinical and radiographic assessment. In addition, they were asked for consent to medical record review to assist in excluding pre-existing inflammatory disease. The inclusion criteria for the current analysis were as follows: age ≥50 years, registered with one of the participating general practices at the time of study, responded to both postal questionnaires, consented to further contact, and attended the research clinic. Participants were excluded if they had incomplete baseline radiographs, had not experienced knee pain within the six months prior to clinic attendance, had a pre-existing diagnosis of inflammatory arthropathy in their medical records, or had had a total knee replacement in their most affected knee. Participants who reported total knee replacement (TKR) after baseline and up to 3 years were also excluded. Patients reporting TKR after 3 years were censored at the 3 year time point.
Baseline data collection
All data were planned and gathered prospectively. At baseline, participants underwent a standardized clinical interview and physical examination conducted by one of six research therapists blinded to the findings from radiography, postal questionnaires and medical records.
Participants filled in a brief self-complete questionnaire about their knee symptoms on the day of their clinic attendance.
Plain knee radiographs were obtained on the day of clinic attendance. Three views were taken of each knee: a weight-bearing semi-flexed posteroanterior (PA) view, according to the protocol developed by Buckland-Wright et al. , and lateral and skyline views, both in a supine position with the knee flexed to 45°. The tibiofemoral joint was assessed using the PA view and the posterior compartment of the lateral view. The patellofemoral joint was assessed using the skyline and lateral views.
Scoring of plain radiographs
A single reader (a consultant rheumatologist with extensive training in assessing knee radiographs for knee OA), blinded to all other information on participants, scored all films. Films were scored for individual radiographic features, including osteophytes, joint space width, sclerosis, subluxation and chondrocalcinosis. PA and skyline views were assigned a Kellgren and Lawrence (K&L) grade based on these authors' original written descriptions . The atlas developed by Burnett et al.  was used for the lateral view.
For PA, K&L score, skyline K&L score and lateral osteophytes, intra- and inter-reader reliability were assessed in a subsample of 50 participants (100 knees) and found to be very good (κ = 0.81–0.98 and 0.49–0.76, respectively) .
Follow-up data collection
Follow up surveys, which included 11-point numerical rating scales (NRS) on current, average and worst knee pain intensity over the past 6 months , were mailed to Phase 2 participants at 18 months, 36 months, 54 months and 72 months.
At baseline and at each follow-up point we classed participants as reporting ‘significant pain variability’ if their recalled worst pain intensity in the past 6 months was ≥5 out of 10 and at least 2 points higher than recalled average pain intensity in the same 6 month period. To be included in the denominator, individuals had to be ‘at risk’ during that interval (i.e. average pain intensity <9 out of 10).
This definition was chosen after referring to previous studies of osteoarthritis flares which were described as worsening usual pain [11, 13], within defined limits using equivocal pain scales from flare design trials which set a minimum threshold of 50 mm on a 100 mm visual analogue scale (VAS)  and a pain increase of at least 20 mm on a 100 mm VAS or an increase of at least two points on a 10 point scale, from baseline [30, 31]. Definitions used in other musculoskeletal disorders such as lower back pain  and non-musculoskeletal conditions such as Chronic Obstructive Pulmonary Disease (COPD) were used [33, 34] where worsening of symptoms is used in addition to requiring different or extra medication. The definitions are all reliant on change and difference in pain.
Predictors available in the CAS(K) dataset were selected for analysis on the basis of being shown in previous studies to be associated with incidence and progression of knee osteoarthritis [15, 35–39], pain outcomes  or acute flare-ups  (Table 1).
The proportion of participants classed as experiencing significant symptom variability was reported for each time point. For each follow-up time point those experiencing symptom variability at baseline were compared between those followed up and not followed up to identify any differences.
To estimate the association between the putative predictor variables and significant pain variability, we used discrete-time survival analysis. For clinical history/examination and radiographic severity predictors we used information from only one knee per individual, the “index knee”: the single painful knee in participants with unilateral knee pain or the most painful knee in individuals with bilateral knee pain. Discrete-time hazard survival models become models for dichotomous response when the data have been expanded to person-period data with one observation for each year the person is at risk. For each follow-up time point, we constructed an indicator variable on whether the patient had experienced significant pain variability in the 6 month period or not and estimated the hazard of significant pain variability using logistic discrete-time hazards model. The outcome was right censored at 72 months, which was the last follow-up time. Individuals who were lost to follow-up or withdrew from the study before the period of significant symptom variability was recorded, were also censored. To adjust for changes in proportion reporting significant pain variability over time, we included dummy variables for each follow-up time in all models. Two sets of analyses were conducted. We first modelled the time to first period of significant pain variability, ignoring additional subsequent periods of significant pain variability reported by the participant. We then used multilevel discrete-time survival (frailty) models to take into account recurrent periods of significant pain variability within participants. In the frailty model method, the association between periods of significant pain variability is explicitly modelled as a random-effect term. The frailty model was estimated using logistic discrete-time hazards model with random effects.
The association between each predictor and outcome was estimated and those with P-value <0.20 were selected for inclusion in the multivariable models. Tests of multicollinearity were performed first by pairwise correlations (one variable excluded if correlation coefficient >0.7) and then by variance inflation factor (VIF >5 considered as evidence of collinearity). We used a manual backward elimination procedure to remove variables from the multivariable model until only factors with a P-value <0.05 were retained in the final model. An a priori decision was made to include age and gender in the final models. All analyses were performed using Stata 13 .
Eight hundred and nineteen people attended the research clinic, of whom 719 participants were eligible for inclusion for the baseline analysis (54% female; mean age 67.3 (SD 8.5) years; mean BMI 29.3 (SD 5.0) kg/m2). There was no strong evidence of selective loss to follow-up related to presence of significant pain variability at baseline (Additional file 1 Table S1).
Participants classed as having at least one period of ‘significant pain variability’
Between 23 and 32% of participants were estimated to have experienced significant pain variability at each of the five time points (Table 2). Across the entire cohort follow up period 363 (47%) participants reported no periods, 202 (27%) reported one period, 90 (12%) reported two periods, 63 (8%) reported three periods, 30 (4%) reported four periods and 13 (2%) reported five periods of significant pain variability. Table 3 presents the descriptive statistics for participants reporting at least one period of significant pain variability.
Factors associated with time to first period of significant pain variability
Based on the outcome of time to first period of significant symptom variability, baseline measures associated with a higher risk of symptom variability in the adjusted analysis were: younger age (OR (per year): 0.96; 95% CI 0.94, 0.97), higher BMI (per kg/m2: 1.03; 1.01, 1.06), higher WOMAC knee pain scores (per unit: 1.05; 1.03, 1.10), longer time since onset (e.g. 1–5 years vs < 1 year: 1.79; 1.16, 2.75) and morning stiffness (≤30 min vs none: 1.43; 1.10, 1.85) (Table 4).
Factors associated with recurrent periods of significant pain variability
Based on the outcome of recurrent periods of significant symptom variability, i.e. allowing for those experiencing more than one episode, baseline measures associated with a higher risk of potential symptom variability in the adjusted analysis were: younger age (0.94; 0.91, 0.98), higher BMI (1.04; 1.00,1.08), higher WOMAC knee pain scores (1.10; 1.03,1.17), longer time since onset (e.g. 1–5 years vs < 1 year: (2.23; 1.11, 4.46) and morning stiffness (≤30 min vs none: 1.67; 1.07, 2.61) (Table 5).
From our study we estimate that between a quarter and a third of adults aged over 50 years with knee pain report significant symptom variability. Such variability was associated with younger age, longer history of knee problem, higher BMI and more severe knee symptoms. Variability was also more common in people reporting previous bilateral knee injury, greater functional limitation, frequent sedentary behaviour and higher anxiety and depression scores at baseline although these associations were not statistically significant after adjusting for covariates.
In the context of previous studies it appears that significant variability in pain affects a large minority of persons with, or at risk, of knee OA but that estimates are sensitive to the definition and period of time and frequency of measurement. Of previous studies employing latent class growth analysis or growth mixture modelling to cohort data with repeated measures of pain only the study by Leffondre et al  identified a group of patients characterised by pain variability. Their group of patients with ‘highly unstable WOMAC total scores, with abrupt changes or short-term fluctuations’ accounted for 18% of the community-dwelling sample of adults aged over 55 years with hip or knee pain. The failure of other studies to extract such a ‘fluctuating pain’ latent class using similar methodology [2–5], may well reflect the long intervals between re-measurements (typically a year). In studies of low back pain, those with weekly or fortnightly pain measurements classed twice as many patients into a ‘fluctuating’ trajectory than studies using monthly measurement . It must also be stressed that within trajectory groups that have an average ‘stable’ trajectory, members of these groups can still experience significant variability in their pain at an individual level. A further source of comparison is Ricci et al.’s  estimate from NHANES I data that 38% of US workers aged 40–65 years with arthritis (predominantly hip or knee pain) report ‘pain exacerbations’. Like our study, they adopted the same magnitude of increase in pain intensity to define these events (2 or more points on 0-10NRS) although the Ricci study was based on a 2-week recall period.
The extent to which our own, and any of these previous studies, provides insights into the frequency of pain exacerbations or flares is limited by the data available. As noted by Marty  and in consensus work for flare definition in other rheumatic diseases [43, 44], flares are probably best thought of as multidimensional constructs. With the data available to us we could not verify the speed of onset, duration, or other features (e.g. swelling, limping) that may be important in distinguishing acute flares from other forms of variability within the natural history of osteoarthritis pain. An important limitation of our study is the potential misclassification bias as a result of recall error. We hypothesise that patients with increased pain closer to the measurement time points may have overestimated their average and worst pain scores whereas those with fewer pain fluctuations or no increase in pain close to the measurement time points are likely to have underestimated their pain scores over the previous 6 months. The overall impact of this on our results is uncertain. In addition, the long period of recall may be particularly prone to ‘forward telescoping’ where an event is reported more recently than it actually happened [45, 46]. In our analysis we have used the ‘average’ and ‘worst’ pain scores taken from the Von Korff pain grade. These were chosen as they were similar but unfortunately not comparable to outcomes used in flare design trials. Flare-ups are identified in drug withdrawal trials by comparing baseline pain scores to worst pain scores. These limitations are only likely to be resolved by prospective studies with frequent repeated measures over clinically relevant time periods incorporating the concept of pain variability
The pattern of associations found in our study is consistent with previous findings for some risk factors but not others. Higher BMI, pain intensity, stiffness, and functional limitation have been found to be associated with flares in previous studies [11, 16]. By contrast, our finding of an increased risk of potential flare with younger age was found by neither Marty nor Ricci which may reflect the duration of data collection. Bouts of heavy physical activity , buckling and knee injury  and worsening mental health  have previously been shown in case-crossover designs to be associated with pain flares. The fact that our study found no association between these factors measured at baseline and episodes of worsened pain occurring months and years later may simply affirm the need to regard these factors as time-varying, proximal triggers. From influential qualitative studies by Gooberman-Hill et al  and Hawker et al , pain variability is thought to be a particular feature in the early and the advanced stages of osteoarthritis. In our study we found no strong relationship between significant variability in pain and severity of radiographic knee OA suggesting that this may happen across the spectrum of the disease. As noted above, our data do not permit us to explore further the quality or predictability of episodes of severe pain: dimensions identified by patients as critical to their ability to cope [12, 50]. If correct, our finding that younger age, male gender, and BMI are associated with higher risk of significant symptom variability, might imply an important role for joint loading in provoking episodes of severe pain and acute flares.
Up to a third of community-dwelling symptomatic adults recall significant variability in knee pain that includes periods of severe pain. Such variability occurs across the spectrum of radiographic severity of knee osteoarthritis. A larger body of work, as has been done for other diseases such as COPD (Chronic Obstructive Pulmonary Disease), is needed to reliably determine the characteristics of those who experience significant symptom variability, including acute flares , to assess burden , and to guide prevention .
Body mass index
The knee clinical assessment study
Chronic obstructive pulmonary disease
36 item short form health survey
Western Ontario & McMaster Universities Osteoarthritis index
Holla JF, van der Leeden M, Heymans MW, et al. Three trajectories of activity limitations in early symptomatic knee osteoarthritis: a 5-year follow-up study. Ann Rheum Dis. 2014;73:1369–75.
Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthr Cartil. 2014;22:622–30.
Nicholls E, Thomas E, van der Windt DA, Croft PR, Peat G. Pain trajectory groups in persons with, or at high risk of, knee osteoarthritis: findings from the Knee Clinical Assessment Study and the Osteoarthritis Initiative. Osteoarthr Cartil. 2014;22:2041–50.
Wesseling J, Bastick AN, ten Wolde S, et al. Identifying Trajectories of Pain Severity in Early Symptomatic Knee Osteoarthritis: A 5-year Followup of the Cohort Hip and Cohort Knee (CHECK) Study. J Rheumatol. 2015;42:1470–7.
Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study. Br J Gen Pract. 2016;66:e32–9.
Soni A, Kiran A, Hart DJ, et al. Prevalence of reported knee pain over twelve years in a community-based cohort. Arthritis Rheum. 2012;64:1145–52.
Cedraschi C, Delézay S, Marty M, et al. Let’s talk about OA pain”: A Qualitative Analysis of the Perceptions of People Suffering from OA. Towards the Development of a Specific Pain OA-Related Questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS One. 2013;8:e79988.
Schneider S, Junghaenel DU, Keefe FJ, et al. Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: Associations with psychological variables. Pain. 2012;153:813–22.
Hawker GA, Stewart L, French MR, et al. Understanding the pain experience in hip and knee osteoarthritis – an OARSI/OMERACT initiative. Osteoarthr Cartil. 2008;16:415–22.
Smith TO, Zou K, Abdullah N, Chen X, Kingsbury SR, Doherty M, Zhang W, Conaghan PG. Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis. Ann Rheum Dis. 2016; doi: 10.1136/annrheumdis-2015-208823.
Marty M, Hilliquin P, Rozenberg S, Valat JP, Vignon E, Coste P, Savarieau B, Allaert FA. Validation of the KOFUS (Knee Osteoarthritis Flare-Ups Score). Joint Bone Spine. 2009;76:268–72.
Rayahin JE, Chmiel JS, Hayes KW, et al. Factors Associated with Pain Experience Outcome in Knee Osteoarthritis. Arthritis Care Res. 2014;66:1828–35.
Esen S, Akarirmak U, Aydin FY, Unalan H. Clinical evaluation during the acute exacerbation of knee osteoarthritis: the impact of diagnostic ultrasonography. Rheumatol Int. 2013;33(3):711–7.
Conrozier T, Mathieu P, Vignon E, et al. Differences in the osteoarthritic synovial fluid composition and rheology between patients with or without flare: a pilot study. Clin Exp Rheumatol. 2010;30:729–34.
Wise BL, Niu J, Zhang Y, Wang N, Jordan JM, Choy E, et al. Psychological factors and their relation to osteoarthritis pain. Osteoarthr Cartil. 2010;18(7):883–7.
Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, HochbergG MC. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Care Res. 2005;53:673–81.
NICE: Chronic Obstructive Pulmonary Disease in over 16 s: diagnosis and management. NICE guidelines [CG101]. https://www.nice.org.uk/Guidance/CG101 (2010). Accessed 19 July 2016.
Global Initiative for Chronic Obstructive Lung Disease. COPD diagnosis, management and prevention. https://www.guidelines.co.uk/gold/copd (2016). Accessed 19 July 2016.
Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology. 2008;47:1213–8.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf (2015). Accessed 19 July 2016.
Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20:453–62.
Peat G, Thomas E, Handy J, Wood L, Dziedzic K, Myers H. The Knee Clinical Assessment Study – CAS(K). A prospective study of knee pain and knee osteoarthritis in the general population. BMC Musculoskelet Disord. 2004;5:4.
Peat G, Thomas E, Handy J, Wood L, Dziedzic K, Myers H. The Knee Clinical Assessment Study – CAS(K). A prospective study of knee pain and knee osteoarthritis in the general population: baseline recruitment and retention at 18-months. BMC Musculoskelet Disord. 2006;7:30.
Buckland-Wright JC, Ward RJ, Peterfy C, et al. Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis. J Rheumatol. 2004;31:1588–97.
Lawrence JS. Rheumatism in Populations. London: Heinemann; 1977. p. 99–100.
Burnett S, Hart D, Cooper C, Spector T. A Radiographic Atlas of OA. London: Springer; 1994.
Duncan RC, Hay E, Saklatvala J, Croft PR. Prevalence of radiographic osteoarthritis - it all depends on your point of view. Rheumatology (Oxford). 2006;45:757–60. doi:10.1093/rheumatology/kei270.
Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50:133–49.
Kivitz A, Makarowski W, Fiechtner J, et al. A flexible daily dosage regimen of oxaprozin potassium in patients with acute knee pain associated with knee osteoarthritis- 24-h analgesic durability and safety. Clin Drug Investig. 2001;21:745–53.
Scott-Lennox JA, Mclaughlin-Miley C, Lennox RD, Bohlig AM, Cutler BL, Yan C, Jaffe M. Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritis. Arthritis Rheum. 2001;44:1599–607.
Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6.
Suri P, Saunders KW, Von Korff M. Prevalence and characteristics of flare-ups of chronic nonspecific back pain in primary care: A telephone survey. Clin J Pain. 2012;28:573–80.
Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(41 suppl):46s–53s.
Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;9:786–96.
Grotle M, Hagen K, Natvig B, Dahl F, Kvien T. Obesity and osteoarthritis in knee, hip and/or hand: An epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord. 2008;9:132.
Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987;30(8):914–8.
Chapple CM, Nicholson H, Baxter GD, Abbott JH. Patient characteristics that predict progression of knee osteoarthritis: A systematic review of prognostic studies. Arthritis Care Res. 2011;63:1115–25.
Conaghan PG, D’Agostino MA, Le Bars M, Baron G, Schmidely N, Wakefield R, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010;69(4):644–7.
Cheung PP, Gossec L, Dougados M. What are the best markers for disease progression in osteoarthritis (OA)? Best Pract Res Clin Rheumatol. 2010;24:81–92.
StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013.
Leffondré K, Abrahamowicz M, Regeasse A, et al. Statistical measures were proposed for identifying longitudinal patterns of change in quantitative health indicators. J Clin Epidemiol. 2004;57:1049–62.
Kongsted A, Kent P, Axen I, Downie AS, Dunn KM. What have we learned from ten years of trajectory research in low back pain? BMC Musculoskelet Disord. 2016;17:220.
Alten R, Pohl C, Choy EH, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. J Rheumatol. 2011;38:1745–50.
Gossec L, Portier A, Landewé R, et al. Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis. 2016;75:991–6.
Cohen G, Conway MA, editors. Memory in the real world. 3rd ed. New York, NY: Psychology Press; 2008.
Tourangeau R, Rips LJ, Rasinski K. The psychology of survey response. Cambridge, UK: Cambridge University Press; 2000.
Zhang Y, Wheaton D, Niu J, Wise B, Havey W, Goggins J, et al. Recent heavy physical activities trigger knee pain exacerbation in persons with symptomatic knee osteoarthritis. Arthritis Rheum. 2011;63.
Zobel I, Erfani T, Bennell KL, et al. Relationship of Buckling and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-Based Case-Crossover Study. Int J of Med Res. 2016. doi:10.2196/ijmr.5452.
Gooberman-Hill R, Woolhead G, Mackichan F, Ayis S, Williams S, Dieppe P. Assessing chronic joint pain: lessons from a focus group study. Arthritis Rheum. 2007;57:666–71.
Hawker GA, Wright JG, Badley EM, Coyte PC. Perceptions of, and willingness to consider, total joint arthroplasty in a population-based cohort of individuals with disabling hip and knee arthritis. Arthritis Rheum. 2004;15:635–41.
Beeh KM, Glaab T, Stowasser S et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013; doi: 10.1186/1465-9921-14-116.
Barnes N, Calverley PM, Kaplan A, Rabe KF. Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med. 2013. doi:10.1186/1471-2466-13-54.
Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Internal Med. 2013;273:584–94.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
Ware Jr J, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.
Bellamy N. WOMAC Osteoarthritis Index. 1996. A Users Guide.
Office for National Statistics. National Statistics Socio-economic Classification (NS-SEC 2002). London: Stationery Office; 2002.
Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical classification criteria for knee osteoarthritis: performance in the general population and primary care. Ann Rheum Dis. 2006;65:1363–7.
The authors thank Professor Peter Croft, Professor Elaine Hay, Dr Elaine Thomas, Dr Laurence Wood, Dr Michelle Marshall, June Handy, Professor Krysia Dziedzic, Dr Helen Myers, Dr Ross Wilkie, Dr Rachel Duncan, Dr Jonathan Hill, Charlotte Clements, Professor Chris Buckland–Wright and Professor Iain McCall for their contributions to the design and acquisition of data for the CAS(K) study. We also thank the administrative and health informatics staff at the Arthritis Research UK Primary Care Centre, staff of the participating general practices and Haywood Hospital, especially Dr Jackie Sakhlatvala, Carole Jackson, Julia Myatt and the Radiographers at the Department of Radiography.
The CAS(K) cohort was supported by the Medical Research Council (Grant G9900220), Arthritis Research UK (Grant 18174), and by Support for Science funding secured by North Staffordshire Primary Care Research Consortium for National Health Service support costs. EP is currently funded by a NIHR In-Practice Fellowship and was previously funded by a NIHR Academic Clinical Fellowship. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Availability of data and material
The datasets analysed during the current study are available from the corresponding author on reasonable request.
The authors contributed to the manuscript as follows: conception and design - GP, EP,RO; analysis and interpretation of data - EP, RO, GP; drafting of the article - EP, GP, RO; final approval - EP, GP, RO. All authors read and approved the final manuscript.
GP has received consultancy fees from InFirst Healthcare Ltd. The authors have no other competing interests to declare.
Consent for publication
Ethics approval and consent to participate
This study involved secondary analysis of anonymised data from the CAS(K) cohort within the cohort objectives approved by North Staffordshire Research Ethics Committee (1430; 03/94; 05/Q2604/72), South Birmingham Research Ethics Committee (06/Q2707/327) and Birmingham East, North, and Solihull Research Ethics Committee (08/H1206/171). All participants provided written consent to take part in the study.
About this article
Cite this article
Parry, E., Ogollah, R. & Peat, G. Significant pain variability in persons with, or at high risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of cohort data. BMC Musculoskelet Disord 18, 80 (2017). https://doi.org/10.1186/s12891-017-1434-3